<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440828</url>
  </required_header>
  <id_info>
    <org_study_id>VAP-2014</org_study_id>
    <secondary_id>2014-001406-17</secondary_id>
    <nct_id>NCT02440828</nct_id>
  </id_info>
  <brief_title>Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia</brief_title>
  <acronym>VAPORISE</acronym>
  <official_title>Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of tobramycin inhalation treatment to standard intravenous
      therapy in the treatment of ventilator associated pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Approximately 9-27% of mechanically ventilated patients in the intensive care unit
      (ICU) develop ventilator-associated pneumonia (VAP). Patients in whom VAP develops have a
      higher mortality rate up to 50%, stay longer in the intensive care unit (ICU), and require
      more resources than those without the disease. Despite the availability of modern ICU care
      and modern antibiotics, the overall clinical cure rate after 72 hours of antibiotic treatment
      for VAP is only 40%. The cure rate for Pseudomonas aeruginosa is even lower. It is unclear
      why VAP cure rates are so low. The ATS guidelines recommend IV antibiotic treatment (IV AB),
      especially directed against gram-negative microorganisms. However, the relatively poor
      response rates seen with intravenous therapy of VAP and the emergence of MDR organisms makes
      new treatment options desirable. The ATS/IDSA VAP guidelines recommend that &quot;adjunctive
      therapy with an inhaled aminoglycoside or polymyxin (colistin) for MDR Gram-negative
      pneumonia should be considered, especially in patients who are not improving&quot;. It is
      therefore necessary to investigate whether adjunctive therapy with inhalation Tobramycin
      could ameliorate prognosis. The recommendations by the Society of Infectious Diseases
      Pharmacists are similar.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response after 72 h of treatment</measure>
    <time_frame>72 hours</time_frame>
    <description>non response is considered when at least one of the following is present
No improvement of the arterial O2 tension to inspired O2 fraction ratio
Persistence of fever (≥38°C) or hypothermia (&lt;35.5°C) together with purulent respiratory secretions
increase in the pulmonary infiltrates on chest radiograph of greater than or equal to 50%
occurrence of septic shock or multiple organ dysfunction syndrome, defined as three or more organ system failures not present on Day 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>day 30</time_frame>
    <description>30-day and 90- day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>day 90</time_frame>
    <description>30-day and 90- day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU survival</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of hospital admittance at day 60</measure>
    <time_frame>day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge from the ICU</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Patients will be followed during ICU stay and evaluated at discharge from ICU, expected average time of discharge is 10 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days at day 28</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of CRP</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of CRP</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of CRP</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of CRP</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of CRP</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of CRP</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of pathogens</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of pathogens</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of pathogens</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of pathogens</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of pathogens</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infectious Score (CPIS)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infectious Score (CPIS)</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infectious Score (CPIS)</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infectious Score (CPIS)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infectious Score (CPIS)</measure>
    <time_frame>discharge ICU, expected average time of discharge is 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>discharge ICU, expected average time of discharge is 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Organ Dysfunction score (MODS)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Organ Dysfunction score (MODS)</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Organ Dysfunction score (MODS)</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Organ Dysfunction score (MODS)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Organ Dysfunction score (MODS)</measure>
    <time_frame>discharge ICU, expected average time of discharge is 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score (SOFA)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score (SOFA)</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score (SOFA)</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score (SOFA)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score (SOFA)</measure>
    <time_frame>discharge ICU, expected average time of discharge is 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Injury Score (LIS)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Injury Score (LIS)</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Injury Score (LIS)</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Injury Score (LIS)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Injury Score (LIS)</measure>
    <time_frame>discharge ICU, expected average time of discharge is 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of procalcitonin (PCT)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of procalcitonin (PCT)</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of procalcitonin (PCT)</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of procalcitonin (PCT)</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of procalcitonin (PCT)</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of procalcitonin (PCT)</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of chest X-ray</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of chest X-ray</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of chest X-ray</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of chest X-ray</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of chest X-ray</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day of normalisation of chest X-ray</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ventilator Associated Pneumonia (VAP)</condition>
  <arm_group>
    <arm_group_label>tobramycin inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice daily placebo inhalation and standard intravenous antibiotics treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin inhalation</intervention_name>
    <description>tobramycin inhalation 300 mg twice daily</description>
    <arm_group_label>tobramycin inhalation</arm_group_label>
    <other_name>Bramitob</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>NaCl 0.9% inhalation 4 ml twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl 0.9% inhalation 4 ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mechanical ventilation 48 hours or more

          -  New or progressive radiologic pulmonary infiltrate

        Together with at least two of the following three criteria (&lt; 24 h):

          -  temperature &gt;38°C

          -  leukocytosis &gt;12,000/mm3 or leucopenia &lt;4,000/mm3

          -  purulent respiratory secretions

        Exclusion Criteria:

          -  patients with allergy to tobramycin

          -  pregnancy

          -  expected to die within 72 hours after enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menno Van der Eerden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rogier Hoek, MD</last_name>
    <phone>+31107034744</phone>
    <email>r.hoek@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Menno Van der Eerden, MD, PhD</last_name>
    <phone>+31107034744</phone>
    <email>m.vandereerden@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rogier Hoek, MD</last_name>
      <phone>+31-10-7034744</phone>
      <email>r.hoek@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Menno Van der eerden, MD, PhD</last_name>
      <phone>+31-10-7034744</phone>
      <email>m.vandereerden@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Torres, MD PhD Prof</last_name>
      <phone>93 227 5779</phone>
      <email>ATORRES@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>R.A.S. Hoek, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

